Vor, with new CEO, changes course to target autoimmune disease
BioPharma Drive: Drug Pricing
JUNE 26, 2025
Published June 26, 2025 Gwendolyn Wu Senior reporter post share post print email license B cells, like those pictured above, malfunction in autoimmune disease. Vor Biopharma licensed a drug in June 2025 that targets proteins essential to B cell survival. But a rocky few years forced Vor to change direction. and European drugmakers.
Let's personalize your content